Fibroblasts are the most abundant mesenchymal cell in human tissues and are primarily responsible for producing the vast majority of extracellular matrix proteins and for generating pathological scars. In response to profibrotic stimuli such as the cytokine transforming growth factor β1 (TGF-β1), fibroblasts undergo a dramatic transformation, including the acquisition of new phenotypes and the adoption of new functional activities. Because fibroblasts play a critical role in the pathogenesis of organ fibrosis and dysfunction, they have long been recognized as a cellular target for therapeutic intervention. For decades, preclinical investigations have sought to target these cells by inhibiting pathways downstream of their major growth factor receptors, although these approaches have yet to translate into any meaningful therapies for patients with fibrotic lung diseases ([@bib1], [@bib2]).

A recent discovery in the pulmonary fibrosis field is that fibroblasts undergo major metabolic changes in response to their activation ([@bib3]). Hallmarks of these changes include a marked increase in glycolysis as well as a significant upregulation in mitochondrial oxygen consumption ([@bib4]--[@bib7]). In general, these changes are believed to be critical for providing fibroblasts with the energy they need for critical functions, and the biosynthetic intermediates for generating the proteins, lipids, and nucleotides necessary for cellular proliferation ([@bib6], [@bib8]). Interestingly, recent experimental studies have shown that inhibition of glycolysis can significantly attenuate activation of fibroblasts *in vitro* and reduce organ remodeling in the lungs of injured mice ([@bib5], [@bib8]--[@bib10]), supporting the notion that metabolic pathways can be targeted in the treatment of pulmonary fibrosis.

Although fibroblasts are believed to rely on glucose as a major energy source, emerging evidence suggests that fibroblasts also use significant amounts of glutamine once they are activated ([@bib6], [@bib11], [@bib12]). Glutamine is the most abundant amino acid in the plasma and has long been used in cell culture medium to support the growth and proliferation of fibroblasts. Once inside the cell, glutamine is metabolized through a process known as glutaminolysis. The first step in this process is the conversion of glutamine to glutamate by the enzyme glutaminase, which then undergoes breakdown to α-ketoglutarate by one of several enzymes. This includes various aminotransferases that reside in mitochondria, such as glutamate-oxaloacetate transaminase and glutamate pyruvate transaminase, which deliver α-ketoglutarate to the tricarboxylic acid cycle for energy production, and various enzymes in the cytoplasm that primarily use α-ketoglutarate for *de novo* synthesis of amino acids. Although it has been reported that fibroblast activation is highly dependent on the presence of glutamine and the activity of glutaminase, it remains unclear whether the breakdown products of glutamine are used mostly in either mitochondria or cytoplasmic compartments.

In this issue of the *Journal*, Hamanaka and colleagues (pp. [597--606](10.1165/rcmb.2019-0008OC)) significantly advance our understanding of glutamine metabolism in lung fibroblasts ([@bib9]). By conducting a series of highly elegant investigations and knocking down various mitochondrial glutamate-metabolizing enzymes, these researchers illustrate that very little, if any, glutamate is used by mitochondria for energy production. In contrast, they show that the vast majority of glutamate is used by cytoplasmic enzymes, including phosphoserine aminotransferase (PSAT1) and Δ1-pyrroline-5-carboxylate synthetase (P5CS), which are enzymes that are essential for producing the amino acids (serine, glycine and proline) needed for collagen production. Importantly, PSAT1 and P5CS were also found to be elevated in fibrotic mouse lungs and in the lungs of patients with idiopathic pulmonary fibrosis, suggesting that increased activity of these enzymes might play a role in the pathobiology of fibrotic lung diseases. Thus, these findings not only serve to advance our understanding of fibroblast metabolism but also lay the foundation for testing novel therapeutic approaches to inhibit pathological scar tissue formation in the lung. Relevant to this, Cui and colleagues recently showed in a different issue of the *Journal* that experimentally induced pulmonary fibrosis could be successfully attenuated by treating mice with a pharmacological inhibitor of glutaminase ([@bib5]). Based on this, we postulate that similar success, perhaps with less off-target effects, might be achieved by targeting the enzymes proposed by Hamanaka and colleagues in this issue.

Although this study adds significantly to our current understanding of fibroblast metabolism, many key questions remain unanswered. For example, if glutamine is primarily used for biosynthetic reactions, why are glycolysis and mitochondrial respiration increased in activated lung fibroblasts? Does this mean that glucose is the primary substrate for energy production and that intermediates of glucose are not used for biosynthetic reactions? Ultimately, investigators could answer these questions by performing carbon-radiolabeling studies to determine the final destination of glucose and glutamine metabolites in cells. This study also does not completely address the implications of knocking down α-smooth muscle actin expression and the potential systemic side effects that could result from fundamentally altering the expression of intercellular structural proteins in cells. That said, the work by Cui and colleagues demonstrated that the upstream inhibition of glutaminase had no meaningful effect on homeostatic processes in the lung ([@bib5]), suggesting that pharmacological effects of targeting glutamine metabolism, at least in the lung, might be restricted to activated fibroblasts.

The pulmonary community is in agreement that new treatments are needed for patients with idiopathic pulmonary fibrosis and other fibrotic lung conditions. This study provides a new direction for the development of alternative approaches to treat these diseases by targeting the pathways involved in glutamine metabolism.
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